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Serotype 1 is an important cause of invasive pneumococcal disease in South Africa and has declined following the introduction
of the 13-valent pneumococcal conjugate vaccine in 2011. We genetically characterized 912 invasive serotype 1 isolates from 1989
to 2013. Simpson’s diversity index (D) and recombination ratios were calculated. Factors associated with sequence types (STs)
were assessed. Clonal complex 217 represented 96% (872/912) of the sampled isolates. Following the introduction of the 13-va-
lent pneumococcal conjugate vaccine (PCV13), ST diversity increased in children <5 years (D, 0.39 to 0.63, P  0.002) and indi-
viduals >14 years (D, 0.35 to 0.54, P < 0.001): ST-217 declined proportionately in children <5 years (153/203 [75%] versus 21/37
[57%], P  0.027) and individuals >14 years (242/305 [79%] versus 96/148 [65%], P  0.001), whereas ST-9067 increased (4/684
[0.6%] versus 24/228 [11%], P < 0.001). Three subclades were identified within ST-217: ST-217C1 (353/382 [92%]), ST-217C2 (15/
382 [4%]), and ST-217C3 (14/382 [4%]). ST-217C2, ST-217C3, and single-locus variant (SLV) ST-8314 (20/912 [2%]) were associ-
ated with nonsusceptibility to chloramphenicol, tetracycline, and co-trimoxazole. ST-8314 (20/912 [2%]) was also associated
with increased nonsusceptibility to penicillin (P < 0.001). ST-217C3 and newly reported ST-9067 had higher recombination ra-
tios than those of ST-217C1 (4.344 versus 0.091, P < 0.001; and 0.086 versus 0.013, P < 0.001, respectively). Increases in genetic
diversity were noted post-PCV13, and lineages associated with antimicrobial nonsusceptibility were identified.
Streptococcus pneumoniae serotype 1 is one of the commonestcauses of invasive pneumococcal disease (IPD) in Africa, Asia,
and South America (1, 2). It usually affects otherwise healthy older
children and young adults (3–5) and has been associated with explo-
sive outbreaks of invasive disease (6–8). Clinically, serotype 1 is asso-
ciated with bacteremia, empyema, and peritonitis and has a lower risk
of mortality relative to other serotypes (5, 9–11). It has high invasive
potential and is rarely detected in colonization studies, remaining
predominantly susceptible to antimicrobial agents (12, 13).
In South Africa, the 13-valent pneumococcal conjugate vac-
cine (PCV13), which includes serotype 1, replaced PCV7 in mid-
2011 (14). A recent epidemiological study in South Africa (5) re-
ported two spatially and temporarily distinct serotype 1 clusters
(with rates significantly higher than the expected baseline) in 2003
to 2004 and 2008 to 2012; however, a decrease in serotype 1 inci-
dence was reported in all age groups following PCV13 introduc-
tion, even compared to years without clusters.
Using multilocus sequence typing (MLST), four geographi-
cally distinct serotype 1 lineages have been described, namely, ST-
306 in Europe and North America, ST-227 in the United States,
ST-615 in Chile, and ST-217 in Africa and Israel (15, 16). A more
recent analysis of 448 serotype 1 genomes from 27 countries (in-
cluding 58 South African isolates from 2004 to 2008) confirmed
the geographic distribution of these lineages and the continued
circulation of ST-217 in South Africa (17).
MLST has been the gold standard for molecular typing for
almost 2 decades (18). Nevertheless, its power to differentiate
lineages is potentially limited by the inclusion of only seven
housekeeping loci and thus may not always accurately reflect
the relatively recent evolutionary biology of an organism (19).
Whole-genome sequencing allows for more in-depth analyses
of MLST-defined lineages. Pneumococci are naturally trans-
formable, and genetic variation occurs predominantly by hor-
izontal gene transfer and recombination (20). Antibiotic expo-
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sure remains a key selective pressure driving the emergence of
recombination-driven resistance (21, 22). In addition, immu-
nological pressure, as a result of pneumococcal immunization,
is a theoretical concern for yielding strains capable of escaping
vaccine-induced protection.
There are limited data describing the circulating genotypes in
South Africa pre- and post-PCV13 introduction. We aimed to
genetically characterize a comprehensive collection of invasive se-
rotype 1 isolates, spanning 25 years, including whole-genome
analyses of a subset of isolates to analyze temporal and/or vaccine
pressure-associated genomic changes that may not be revealed by
MLST.
(This work was presented in part at the 9th International Sym-
posium on Pneumococci and Pneumococcal Diseases, Hy-
derabad, India, 9 to 13 March 2014 [23]).
MATERIALS AND METHODS
Historical isolates from 1979 to 1998. Since 1979, the former South Af-
rican Institute for Medical Research (whose functions were later absorbed
by the National Health Laboratory Service in 2001) served as the national
reference center for pneumococcal serotyping and monitoring of antimi-
crobial resistance (24–26). This was initiated following the discovery of
the first multidrug-resistant pneumococcal isolate in 1977 in South Africa
(27). Storage of isolates was not systematic; however, 23 randomly se-
lected serotype 1 isolates believed to be representative of isolates collected
at the time were available for characterization.
IPD surveillance from 1999 to 2013. Systematic national laboratory-
based surveillance for IPD was initiated mid-1999 (28). Surveillance was
enhanced in 2003 at select sentinel hospitals in all provinces, and addi-
tional clinical and demographic data were collected (2, 5). Approximately
200 laboratories throughout the country, which perform clinical micro-
biology diagnostic tests, submit reports of laboratory-confirmed IPD to-
gether with isolates to the reference laboratory at the National Institute for
Communicable Diseases. IPD was defined as illness associated with the
detection of S. pneumoniae from normally sterile site specimens. Quar-
terly regional laboratory audits identified previously unreported cases.
Sampling strategy. Serotype 1 data analyzed in this project were amal-
gamated from three different projects (see Table S1 in the supplemental
material): for project 1, traditional MLST (i.e., PCR amplification and
Sanger sequencing of 7 housekeeping genes) was performed on isolates
with PCV serotypes collected prior to PCV introduction, namely, 2007
and 2011 (pre-PCV13). Isolates collected in 2012 and 2013 (early post-
PCV13) were characterized by whole-genome sequencing. All viable iso-
lates from children 5 years of age were selected for MLST. Due to the
high numbers of isolates available for older individuals (5 years), half of
all viable serotype isolates were selected for MLST. Where isolates failed to
grow or yield an MLST result (due to nonamplification of some alleles or
poor/incomplete sequence data), they were not replaced by selecting an-
other isolate.
For project 2, whole-genome sequencing was performed on all avail-
able historical serotype 1 strains collected between 1989 and 1998 (n 
23), prior to the initiation of national laboratory-based surveillance for
IPD. In addition, serotype 1 isolates collected over 15 years, from 1999 to
2013, through our national surveillance program for IPD were selected for
whole-genome sequencing. The selection of isolates from each year was
random, with a bias toward children (3:1 ratio of children to adults). For
the selection process, children and adults were defined by ages of 15
years and 15 years, respectively.
For project 3, we sampled 300 invasive pneumococci per year over a
period of 9 years (2005 to 2013) from isolates representing all serotypes,
collected through our national surveillance. Isolate selection was random
with respect to serotype and was stratified by age, namely, 150 isolates
from children age 0 to 2 years, and 75 isolates each from children age 3 to
5 years and individuals who were 6 years. Data for serotype 1 isolates
were extracted and included in this study.
Phenotypic characterization. Identification was confirmed by stan-
dard microbiological methods (29), and serotyping was performed by the
Quellung reaction using serotype-specific antisera (Statens Serum Insti-
tut, Denmark). Antimicrobial susceptibility testing was performed by
broth microdilution using Clinical and Laboratory Standards Institute
guidelines and breakpoints, as previously described (2). Multidrug resis-
tance was defined as nonsusceptibility to three or more of the following
drug classes: penicillin, erythromycin, chloramphenicol, tetracycline, ri-
fampin, or trimethoprim-sulfamethoxazole (co-trimoxazole).
Molecular characterization. Sampling of serotype 1 isolates for mul-
tilocus sequence typing (MLST) (n  378) and whole-genome sequencing
(n  534) is summarized in Table S1 in the supplemental material. MLST
was performed as previously described (30, 31). For genome sequencing,
DNA was extracted from overnight broth cultures using the QIAamp
DNA minikit (Qiagen, Inc., USA). Extracted DNA for 479/534 (90%)
isolates was shipped to the Wellcome Trust Sanger Institute, United King-
dom, where paired-end whole-genome sequencing using index-tagged
libraries was carried out using the Illumina HiSeq. The remaining 55
genomes were sequenced in South Africa; libraries were prepared using
the Nextera XT DNA sample preparation kit (Illumina, USA), and se-
quencing was performed on an Illumina MiSeq.
MLST analysis. The eBURST version 3 algorithm was applied to gen-
erate population snapshots and determine founding genotypes and pat-
terns of evolutionary descent between related sequence types (ST) (32). A
clonal complex was defined as a cluster of related STs, whereby all STs
were linked as single-locus variants (SLV) to another ST in the group. ST
diversity was calculated using Simpson’s diversity index (D). D ranges
from 0 to 1, and values closer to 1 indicate higher diversity. STs were
stratified by the age groups 5 years, 5 to 14 years, and 14 years, and
PCV periods pre-PCV13 (1989 to 2011) versus early post-PCV13 (2012 to
2013).
Genome assembly and annotation. Internal automated pipelines de-
veloped by the Wellcome Trust Sanger Institute were used to assemble
and annotate the genome. The assembly pipeline used Velvet, SSPACE,
GapFiller, and SMALT (33–35) to produce a set of scaffold contigs, fol-
lowing which the annotation was run automatically on all assemblies with
the pipeline using Prokka (36). STs were extracted using a script available
at https://github.com/sanger-pathogens/mlst_check. The assembled
reads were uploaded to PubMLST.org to identify the 53 ribosomal pro-
tein-encoding loci from the whole-genome data (37).
Whole-genome phylogeny. Phylogenetic relationships between iso-
lates were assessed using whole-genome MLST (wgMLST) (31) and sero-
type 1 ST-227 (accession no. FQ312030) as an annotated reference ge-
nome. The selected BLASTN parameters used a cutoff of 70% identity
over a 50% alignment, with a word size of 20 and core genome threshold
of 90%. The distance matrix obtained for the genomes on the basis of core
alleles was used to construct a phylogenetic tree using the neighbor-join-
ing algorithm in SplitsTree version 4.13.1 (38).
Recombination and resistance. The sequence read data were mapped
to the S. pneumoniae INV104B genome (serotype 1, ST-227, accession no.
FQ312030) using SMALT (https://www.sanger.ac.uk/resources/software
/smalt/) to produce a whole-genome alignment for all isolates. Genealo-
gies Unbiased By recomBinations In Nucleotide Sequences (Gubbins)
was used to identify regions within the genome alignment in which single
nucleotide polymorphisms (SNPs) may have been introduced in a block
by recombination (39). This iterative algorithm generated tab files show-
ing the location of potential recombination, and a maximum-likelihood
phylogeny was generated based on the putative point mutations outside
these regions of high sequence diversity. The ratios of recombination
events relative to point mutations (rho/theta), and of base substitutions
imported through recombination to those occurring through point mu-
tation (r/m), were calculated using the Gubbins output (19, 21). Antibi-
otic Resistance Gene-Annotation (ARG-ANNOT) was used to screen for
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the presence/absence of known antimicrobial resistance determinants
(40).
Statistical analyses. Age-specific incidence rates for years 2003 to 2013
were calculated using population data available from Statistics South Af-
rica (http://www.statssa.gov.za/). The 2 test for trend was used to deter-
mine linear trends over time for incidence. Differences in proportions
were assessed using the 2 or Fisher’s exact tests. Factors associated with
rho/theta (ratio of the number of recombination events to point muta-
tions) of serotype 1 overall and among the three ST-217 clades (as deter-
mined by whole-genome phylogeny) were assessed using linear regres-
sion. In addition, factors associated with ST-217 clades and antimicrobial
susceptibility associated with the most commonly detected STs were as-
sessed using multinomial regression. Multinomial regression allows mod-
eling of outcome variables with more than two categories and relates the
probability of being in category j to the probability of being in a baseline or
reference category. A complete set of coefficients were estimated for each
of the j levels (ST-217C2, ST-217C3, and other commonly detected STs)
that were compared with the baseline category (ST-217C1), and the effect
of each predictor in the model was measured as a relative risk ratio (RRR).
ST-217C1 was chosen as the reference category, as it was the most repre-
sented cluster. Significance was assessed with two-sided P values of 0.05
for all models. Statistical analyses were implemented using Stata version
11 (StataCorp).
Ethical considerations. Ethical approval for national surveillance
(which includes isolate characterization) was obtained through the hu-
man ethics research committee (medical) at the University of the Witwa-
tersrand, Johannesburg, South Africa (protocol no. M140159).
Nucleotide sequence accession numbers. The newly deposited Euro-
pean Nucleotide Archive accession numbers are ERR1197531 to
ERR1197628, ERR352058 to ERR352076, ERR387554 to ERR387648
(excluding ERR387589 and ERR387646), ERR568438, ERR568446,
ERR568447, ERR568448, ERR568456, ERR568468, ERR568471, ERR568481,
ERR568515, ERR568535, ERR568536, ERR568539, ERR568552, ERR568559,
ERR568563, ERR568568, ERR568583, ERR568586, ERR568593, ERR568601,
ERR568625, ERR568631, ERR568632, ERR568656, ERR568660, ERR568664,
ERR568668, ERR568671, ERR568679, ERR568696, ERR568715, ERR568718,
ERR568739, ERR568747, ERR568749, ERR570410, ERR570419, ERR570426,
ERR570430, ERR570437, ERR570452, ERR570476, ERR586465, ERR586468,
ERR600315, ERR600318, ERR600322, ERR600325, ERR600333, ERR600341,
ERR600343, ERR600346, ERR600357, ERR600362, ERR600378, ERR600379,
ERR600394, ERR600396, ERR600397, ERR600408, ERR600424, ERR600426,
ERR600431, ERR600441, ERR600447, ERR600464, ERR600471, ERR600472,
ERR600473, ERR600477, ERR600486, ERR600493, ERR600513, ERR600526,
ERR600534, ERR600539, ERR600544, ERR600550, ERR600558, ERR600561,
ERR600571, ERR600580, ERR600592, ERR600593, ERR600594, ERR600619,
ERR632868, ERR632882, ERR632885, ERR632892, ERR632896, ERR632897,
ERR632903, ERR632914, ERR632921, ERR632929, ERR632940, ERR632943,
ERR632977, ERR632979, ERR632990, ERR632991, ERR633016, ERR633029,
ERR633037, ERR633039, ERR633042, ERR633048, ERR633060, ERR633061,
ERR633063, ERR633073, ERR633090, ERR633096, ERR633104, ERR633113,
ERR646570, ERR646575, ERR646582, ERR646598, ERR646599, ERR701778,
ERR701781, ERR701782, ERR701793, ERR701809, ERR701821, ERR701837,
ERR701846, ERR701849, ERR701855, ERR701860, ERR708301, ERR714475,
ERR714491, ERR714502, ERR714509, ERR714539, ERR714541, ERR714553,
ERR714568, ERR714576, ERR714580, ERR714590, ERR714591, ERR714593,
ERR714607, ERR714617, ERR714620, ERR714621, ERR714625, ERR714628,
ERR714630, ERR714633, ERR714634, ERR714635, ERR714636, ERR714648,
ERR714649, ERR714658, ERR714660, ERR714662, ERR714663, ERR714666,
ERR714668, ERR714680, ERR714694, ERR714712, ERR730521, ERR730538,
ERR730542, ERR730543, ERR730552, ERR730587, ERR730592, ERR730597,
ERR730608, ERR730609, ERR730649, ERR730651, ERR730659, ERR730666,
ERR730684, ERR730687, ERR730708, ERR730709, ERR730714, ERR730728,
ERR730731, ERR730736, ERR730738, ERR730751, ERR730778, ERR730780,
ERR730826, ERR730827, ERR730831, ERR730854, ERR730872, ERR730874,
ERR730877, ERR730881, ERR730888, ERR730893, ERR730914, ERR730916,
ERR730924, ERR736903, ERR736911, ERR736939, ERR773817. ERR773820,
ERR773825, ERR773827, ERR773832, ERR773845, ERR773850, ERR773851,
ERR773856, ERR773862, ERR773865, ERR773875, ERR773878, ERR773882,
ERR773892, ERR773901, ERR773902, ERR773905, ERR773915, ERR773924,
ERR773930, ERR773937, ERR773939, ERR773940, ERR773943, ERR773949,
ERR773957, ERR773970, ERR773975, ERR773982, ERR773985, ERR773990,
ERR773996, ERR774001, ERR774008, ERR774015, ERR774016, ERR774020,
ERR774022, ERR774023, ERR774057, ERR774075, ERR774078, ERR774080,
ERR774081, ERR774085, ERR774092, ERR774093, ERR774134, ERR774144,
ERR774287, ERR774288, ERR774293, ERR774301, ERR774302, ERR774315,
ERR774317, ERR774336, ERR774369, ERR774373, and ERR774376.
RESULTS
National surveillance from 1999 to 2013. During this period,
53,647 cases of IPD were reported, of which 39,543 (74%) had
viable isolates. From 2003 through 2009, the average incidences of
serotype 1 disease were 1.1, 0.9, and 0.9 per 100,000 population in
the 5 years, 5 to 14 years, and 14 years age groups, respectively.
By 2013, the incidences declined to 0.19, 0.24, and 0.32 in the three
age groups, respectively (P  0.001). Serotype 1 was the most
common IPD serotype in the pre- and post-PCV13 periods, ac-
counting for 5,315 (13%) of the viable isolates (see Fig. S1A and B
in the supplemental material). One percent (61/5,315) were non-
susceptible to penicillin, with an MIC50 of 0.12 g/ml, compared
to 37% (12,591/34,230) penicillin nonsusceptibility among non-
serotype 1 isolates (MIC50, 0.25 g/ml) (P  0.001). Rates of
serotype 1 nonsusceptibility to other antimicrobials were 12%
(628/5,315), 6%, (324/5,315), 5% (252/5,315), 0.8% (41/5,315),
0.5% (28/5,315), and 0.3% (16/5,315) to co-trimoxazole, tetracy-
cline, chloramphenicol, rifampin, erythromycin, and clindamy-
cin, respectively. Multidrug resistance to any drug class was pres-
ent in 4% (214/5,315) of serotype 1 isolates, whereas only 0.6%
(32/5,315) were nonsusceptible to penicillin and two other drug
classes. Epidemiological trends for serotype 1 disease from 2003 to
2013 have been described elsewhere (5).
eBURST population structure. MLST data were available for
912 serotype 1 isolates; however, the population snapshots (Fig.
1A to C) include only those isolates for which patient age was
known (n  894). Sequence types, by age group and PCV period,
are summarized in Table S2 in the supplemental material. Popu-
lation snapshots were generated for each of the three age groups
(5 years, 5 to 14 years, and 14 years), and for pre- and early
post-PCV13 periods. ST-217 accounted for 72% (642/894) of the
isolates (excluding single-locus variants), and ST-217 clonal com-
plex (including single-locus variants) accounted for 97% (866/
894) of the isolates. Overall, ST diversity (D) was similar among
isolates from all three age groups, namely, 0.43 (95% confidence
interval [CI], 0.37 to 0.50), 0.53 (95% CI, 0.46 to 0.59), and 0.42
(95% CI, 0.36 to 0.47). ST diversity was relatively constant from
1999 to 2013 and trended toward increased diversity in 2012 and
2013 (see Fig. S2 in the supplemental material). Sequence type
diversity (D), from the pre-PCV13 to post-PCV13 periods, in-
creased from 0.39 to 0.63 (P  0.002) in children 5 years and
from 0.35 to 0.54 (P  0.001) in individuals 14 years (Fig. 1A
and C). Overall, the percentage of ST-217 isolates declined from
75% (153/203) to 57% (21/37) in children 5 years pre- and
post-PCV13 introduction (P  0.027). Similarly, in individu-
als 14 years, ST-217 declined from 79% (242/305) to 65% (96/
148) (P  0.001). ST-612 declined from 27% (43/158) to 12%
(5/43) in the 5- to 14-year group after PCV13 introduction (P 
0.043). The newly reported ST-9067 increased proportionately
du Plessis et al.
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from 0.6% (4/684) in the pre-PCV13 period to 11% (24/228) in
the post-PCV13 period (P  0.001). ST-9067 was detected only in
younger individuals (0 to 14 years) prior to PCV-13 introduction,
but was detected predominantly in older individuals (14 years)
post-PCV13 introduction (17/24 [71%]) (P  0.016). In the 5- to
14-year age group, sequence type diversity remained unchanged
(D, 0.51 versus 0.56, P  0.616) before and after PCV13 introduc-
tion.
Genomic population structure. Complete genomes were
available for 534/912 (59%) isolates, with 428 and 106 genomes
from the pre-PCV13 and early post-PCV13 periods, respectively.
Using SNP analysis (Fig. 2) and wgMLST (see Fig. S3 in the sup-
plemental material), the isolates clustered predominantly by se-
quence type. The largest clade (ST-217C1) comprised ST-217 (n 
353) and the newly reported SLV ST-9067 (n  16). The ST-612
(SLV of ST-217) clade (n  101) was the closest relative to ST-
217C1, followed by triple-locus variant ST-618 (n  17). Two ad-
ditional ST-217 clades were identified (ST-217C2 [n  15] and
ST-217C3 [n  14]), which clustered more distantly from ST-
217C1. ST-217C3 isolates clustered with SLV ST-8314 (n  8).
Ribosomal MLST profiles differed among the three ST-217 clades:
ribosomal ST 3462 (rST-3462) (n  187/352 [53%]) and rST-
3467 (n  103/352 [29%]) were common among ST-217C1 iso-
lates. The majority of ST-217C2 isolates (n  13/15 [87%]) were
rST-591, whereas ST-217C3 isolates were a mixture of four differ-
ent ribosomal STs, with the most common being rST-4616 (5/14
[36%]). Multinomial logistic regression showed no association
between ST-217 clades and gender, age group, or HIV status. ST-
217C3 was more likely to cause disease in the post-PCV13 era than
ST-217C1, but this was not statistically significant (RRR, 2.03; 95%
CI, 0.617 to 6.709; P  0.243).
Recombination. Genome characteristics, by sequence type,
are summarized in Table 1. Using ST-217C1 as the reference
group, the mean recombination ratios r/m and rho/theta did not
vary significantly between sequence types, with the exception of
ST-217C3, which had a mean r/m of 4.344 (95% CI, 2.951 to 5.739;
P  0.001) compared to ST-217C1 (mean r/m, 0.091), and ST-
9067, which had a higher rho/theta (0.086) than that of ST-217C1
(0.013; 95% CI, 0.036 to 0.110, P  0.001). Overall, rho/theta for
ST-217 increased from 0.010 prior to PCV13 introduction to 0.039
post-PCV13 (P  0.002). In the univariate analysis (Table 2), rho/
theta among all serotype 1 isolates was higher post-PCV13 intro-
FIG 1 Population snapshot showing relationships between sequence types of invasive pneumococcal serotype 1 from children 5 years (A), 5 to 14 years (B),
and 14 years (C), pre- and post-PCV13, South Africa, 1989 to 2013. Blue denotes founding genotype and circle size is indicative of number of isolates.
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duction (0.044 versus 0.010 [P  0.001]) and in individuals 14
years (0.032 versus 0.008 [5 years] [P  0.002]). Serotype 1
isolates from HIV-positive individuals had a significantly lower
rho/theta than that of isolates from HIV-negative individuals
(0.001 versus 0.029, P  0.018). In the multivariable model, only
HIV status remained significantly associated with recombination
(P  0.019).
Antimicrobial resistance. The majority of ST-217C3 isolates
were nonsusceptible to co-trimoxazole (13/14 [93%]), and 29%
(4/14) were nonsusceptible to chloramphenicol and tetracycline
(Table 3). For ST-8314 isolates, 90% (18/20), 85% (17/20), 70%
(14/20), and 15% (3/20) were nonsusceptible to co-trimoxazole,
chloramphenicol, tetracycline, and penicillin, respectively. In the
multinomial model, compared to ST-217C1, ST-217C2, ST-217C3,
and ST-8314, isolates were significantly associated with increased
nonsusceptibility to co-trimoxazole, chloramphenicol, and tetra-
cycline (P  0.001). In addition, ST-8314 was associated with
increased nonsusceptibility to penicillin (P  0.001). tet(M) and
chloramphenicol acetyltransferase (catpC194) genes were con-
firmed in ST-217C2, ST-217C3, and ST-8314 isolates with pheno-
typic nonsusceptibility. The conjugative transposon Tn916 was
confirmed to flank tet(M) in these isolates.
DISCUSSION
Serotype 1 remains the most common serotype causing IPD in
South Africa; however, reductions in incidence were noted post-
PCV13 introduction. ST-217 remained predominant throughout
the period of analysis, although increases in ST diversity were
FIG 2 Maximum-likelihood phylogenetic tree, based on whole-genome single nucleotide polymorphisms outside recombination blocks, showing relationships
between invasive serotype 1 isolates (n  534) from South Africa, 1989 to 2013. Clusters are colored according to sequence type. ST-227 (accession no.
FQ312030) was used as a reference.






Mean (SD) no. of SNPs
outside recombination sitesa
Mean (SD) no. of
recombination blocksb
Mean
rho/thetac P valued Mean r/me P valued
ST-217 (All) 382 1,918,345 8 (9) 0.24 (1) 0.015 0.283
ST-217C1 353 1,919,081 7 (8) 0.16 (0.7) 0.013 Ref 0.091 Ref
ST-217C2 15 1,903,232 13 (11) 0.67 (0.2) 0.035 0.253 0.934 0.220
ST-217C3 14 1,915,989 26 (16) 1.64 (4) 0.032 0.360 4.436 0.001
ST-304 1 2,042,749 330 52 0.157 0.051 11.524 0.001
ST-306 4 2,033,949 8 (5) 0.25 (0.43) 0.019 0.871 0.173 0.950
ST-611 5 1,934,828 16 (22) 0.20 (0.4) 0.009 0.911 0.076 0.990
ST-612f 101 1,915,591 8 (8) 0.26 (1) 0.012 0.866 0.610 0.078
ST-618 17 1,917,230 19 (18) 0.06 (0.2) 0.001 0.514 0.081 0.987
ST-8314f 8 1,900,792 7 (4) 0.04 (1) 0.038 0.357 0.625 0.567
ST-9067f 16 1,907,652 6 (6) 0.56 (1) 0.086 0.001 0.813 0.279
a SNP, single nucleotide polymorphism.
b A recombination block was defined as 3 consecutive SNPs.
c rho/theta is the ratio of the number of recombination events to point mutations, a measure of the relative rates of recombination and point mutation (6, 11).
d ST-217C1 was the reference group for comparing rho/theta and r/m between sequence types.
e r/m is the ratio of base substitutions predicted to have been imported through recombination to those occurring through point mutation.
f Single-locus variant of ST-217.
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observed post-PCV13 introduction. A decline in ST-217 and ST-
612 was observed, whereas newly reported ST-9067 increased in
proportion in the sampled population. Although largely suscepti-
ble to all antimicrobials tested, there were sublineages of ST-217
associated with increased nonsusceptibility to chloramphenicol,
tetracycline, and co-trimoxazole. ST-8314 was also associated
with increased nonsusceptibility to penicillin.
ST-217 accounted for the large majority of serotype 1 isolates.
Although this lineage is common to Africa and Israel (16, 41),
early isolates were identified in northern Europe and, due to its
global dissemination, it was designated Sweden1-27 by the Pneu-
mococcal Molecular Epidemiology Network (PMEN) (42, 43).
During the late 1980s, Sweden experienced an increase in pneu-
mococcal bacteremia due to serotypes 1 and 14. Although MLST
identified predominantly the European/North American clone
(ST-306) among the Swedish serotype 1 isolates, ST-217 was iden-
tified in one isolate. ST-217 has also been reported in the United
States, albeit rarely (3, 15).
Our data set has serotype 1 ST-217 isolates dating back to 1991,
and the fact that this clone remained predominant throughout the
25-year period indicates a measure of genetic stability among se-
rotype 1 isolates in South Africa. However, sequence type diversity
increased in young children (5 years) and older individuals
(14 years) following PCV13 introduction. Most noteworthy was
the overall decline in the percentage of ST-217 isolates and the
apparent expansion of newly reported ST-9067 within the sam-
pled data set. ST-9067 had a significantly higher recombination
ratio than that of ST-217C1, which may explain its possible expan-
sion following PCV13 introduction; however, the impetus for this
is unknown, given that it is fully susceptible to all tested antimi-
crobials. In the United States, the increase in serotype 19A
post-PCV introduction was thought to be driven, at least in
TABLE 2 Univariate and multivariable analyses of the ratio of
recombination events to point mutations (rho/theta) among invasive






















Post-PCV13 106 0.044 0.035 0.001 0.022 0.120
Gender
Female 226 0.017
Male 273 0.017 0.000 0.971 NAc
Age group (yr)
5 188 0.008
5–14 144 0.010 0.002 0.780 0.014 0.348
14 184 0.032 0.024 0.002 0.024 0.109
HIV status
Negative 52 0.029
Positive 67 0.001 0.028 0.018 0.031 0.019
a rho/theta is the ratio of the number of recombination events to point mutations, a
measure of the relative rates of recombination and point mutation (6, 11).
b Pre-PCV13 was defined as 1989 to 2011; early post-PCV13 was defined as 2012 to
2013.
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part, by the expansion of antibiotic-resistant clonal complex
320 (CC320) (44). Genomic surveillance of pre- and post-PCV
invasive pneumococci of all serotypes from adults in the Neth-
erlands showed a temporary decline in genetic diversity follow-
ing PCV7 use (45).
Phylogenetic analyses revealed three distinct clades within the
ST-217 lineage, indicating a level of resolution beyond that of the
traditional 7-locus MLST. This subdivision of the ST-217 clone
was not evident in a recent analysis of serotype 1 isolates (which
included 58 genomes from South Africa), presumably because of
the smaller sample size and shorter time frame (5 years) in which
the South African isolates were collected for that study (17).
Whole-genome phylogeny revealed the unusual clustering of
ST-9067 and ST-8314 with ST-217C1 and ST-217C3 isolates,
respectively. It also showed that ST-217C1 was more closely
related to SLV ST-612 (an older more established lineage de-
tectable in South Africa since 2000) than ST-217C2 or ST-
217C3. ST-611 and ST-618 isolates, neither of which belong to
the ST-217 clonal complex, were also more closely related to
ST-217C1 than ST-217C2 and ST-217C3. Nevertheless, ST-618
shares four MLST alleles with ST-217, indicating some degree
of relatedness and potentially justifying the clustering with ST-
217C1. There were several additional ST-217 SLVs that emerged
in the same year that PCV13 was introduced (2011); however,
these sequence types were not sustained and disappeared in
2012. We were not able to assess their relationships relative to
the other sequence types at the whole-genome level, as we did
not have those data.
Since pneumococcal diversification is predominantly due to
genetic exchange caused by interaction with other pneumococci
and closely related streptococcal species in the nasopharynx, a
short duration of carriage is thought to limit this exchange and
thus stabilize the genome. The recombination ratio gives an indi-
cation of how diversity is arising in the population. Croucher et al.
(19) showed a high degree of recombination in a single multidrug-
resistant pneumococcal lineage (PMEN1, Spain23F-1), in which
88% diversity was introduced by recombination. Recombination
ratios for isolates representing multidrug-resistant globally dis-
seminated clones (19, 22, 46, 47) were significantly higher (rang-
ing from 7.2 to 34.1) than those for our ST-217C1 and ST-217C2
clades (0.09 and 0.93, respectively). The recombination ratio for
ST-217C3 was significantly higher than that for ST-217C1 at 4.4
and more comparable to that of PMEN lineages. The recently
published global serotype 1 genomic study reported similarly
low recombination ratios, ranging from 0.03 (for the South
African and Mozambique isolates) to 0.14 (for the West Afri-
can isolates) (17).
The short duration of carriage of serotype 1 is possibly respon-
sible for the low levels of antibiotic resistance (6). Genomic anal-
yses of 3,000 pneumococcal carriage isolates showed that re-
combination coincided with genes associated with antibiotic
resistance (21). In our study, crude analysis of the recombination
hotspots showed increased recombination at the folP locus (to-
gether with folC and folE, both of which are involved in folate
biosynthesis) in the co-trimoxazole-resistant ST-217C2 and ST-
217C3 clades (data not shown). Co-trimoxazole is widely used in
South Africa as a prophylactic in HIV patients, and S. pneumoniae
has been shown to have high rates of nonsusceptibility to this drug
(48). Nonetheless, serotype 1 was predominantly susceptible to
co-trimoxazole and, more importantly, penicillin, which remains
the drug of choice for the treatment of pneumococcal pneumonia.
The multidrug-resistant ST-217C2 and ST-217C3 clades accounted
for a small proportion of isolates overall (10%) and may either
proliferate under the selective pressure of co-trimoxazole use or
may decline altogether as serotype 1 IPD declines through contin-
ued PCV13 use. If ST-8314 were to expand, this would be of
greater concern because of its association with penicillin resis-
tance. Almost half (8/17) of the penicillin-susceptible ST-8314
isolates had MICs of 0.06 g/ml (data not shown), indicating a
trend toward nonsusceptibility. Multidrug resistance can be ac-
quired through transposons, which may carry one or several re-
sistance determinants. Their integration causes changes to the
host genome and, in this study, these changes were reflected
through the identification of ST-217 subclades. Tetracycline
and/or macrolide resistance has been shown to be associated with
the Tn916/Tn1545 family of conjugative transposons, and, in par-
ticular, Tn916, which carries the tet(M) resistance determinant
(49).
An interesting observation was the significantly lower recom-
bination ratio (rho/theta) observed in serotype 1 isolates from
HIV-positive individuals compared to that of HIV-negative indi-
viduals. This might seem surprising given the relatively high pneu-
mococcal colonization rate observed among HIV-infected adults
compared with those who are HIV uninfected (50), which should
increase the reservoir of genes available for genetic exchange. Nev-
ertheless, reduced selective pressure from an immunosuppressed
host may limit the need for genetic exchange.
This analysis includes approximately 20% of serotype 1 isolates
collected during this period, with sampling bias for some years,
and nonsystematic collection of historical isolates prior to 1999.
Thus, our data set may not accurately reflect temporal or vaccine-
associated changes in serotype 1. Only 2 years of post-PCV13 data
were included; hence, potentially consequential vaccine-associ-
ated genotypic changes are probably unlikely to have occurred at
this stage. Nevertheless, this study highlights the predominance of
a successful globally disseminated serotype 1 clone, with increased
sequence diversity in the sampled population, following PCV13
introduction. Antimicrobial-nonsusceptible subclades provide
the potential to become more widespread and merit the continued
monitoring of serotype 1 genotypes following PCV13 introduc-
tion.
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